0000816956-26-000009
SEC filingCONMED Corporation reported net sales of $1.37 billion for fiscal year 2025, generating gross profit of $750.5 million and net income of $47.1 million. The company achieved operating income of $102.6 million and comprehensive income of $59.6 million. Operating cash flow was strong at $170.7 million, while free cash flow was $149.7 million after accounting for capital expenditures. The balance sheet shows total assets of $2.33 billion, with shareholders' equity of $1.03 billion and total liabilities of $1.29 billion, including long-term debt of $834.2 million. The company maintained a solid liquidity position with $40.8 million in cash and cash equivalents. Earnings per share were $2.00 both basic and diluted. The financial results demonstrate the company's ability to generate cash from operations while managing its capital structure.
CONMED Corporation reported fiscal year 2025 results with net sales of $1.37 billion. The company generated gross profit of $750.5 million from cost of sales of $624.2 million. Operating expenses totaled $647.9 million, consisting of $592.0 million in selling and administrative expenses and $55.9 million in research and development. This resulted in operating income of $102.6 million. After interest expense of $31.1 million and other expense of $418,000, income before taxes was $71.1 million. Provision for income taxes was $24.1 million, yielding net income of $47.1 million. Comprehensive income was $59.6 million, including other comprehensive income of $12.6 million net of tax. Earnings per share were $2.00 for both basic and diluted calculations.
The company reported net sales of $1.37 billion for fiscal year 2025. No segment breakdown or geographic mix information was provided in the available data. The revenue figure represents the total consolidated sales for the period ending December 31, 2025. The document does not contain specific information about revenue growth drivers, product line performance, or customer segment analysis. All revenue-related information is limited to the consolidated net sales figure of $1.37 billion as reported in the income statement.
Gross margin for fiscal year 2025 was 54.8%, calculated from gross profit of $750.5 million on net sales of $1.37 billion. Operating margin was 7.5%, derived from operating income of $102.6 million divided by net sales. The cost structure shows selling and administrative expenses of $592.0 million (43.2% of sales) and research and development expenses of $55.9 million (4.1% of sales). Total operating expenses were $647.9 million, representing 47.3% of net sales. Net income margin was 3.4%, calculated from net income of $47.1 million divided by net sales of $1.37 billion.
Operating cash flow was $170.7 million for fiscal year 2025, generated from net income of $47.1 million plus various adjustments including depreciation of $17.1 million, amortization of $57.1 million, and stock-based compensation of $28.3 million. Investing activities used $21.0 million, primarily for purchases of property, plant and equipment of $19.8 million. Financing activities used $135.8 million, including $99.8 million in term loan payments and $24.7 million in dividends paid. Free cash flow was $149.7 million (operating cash flow of $170.7 million minus capital expenditures of $21.0 million). The balance sheet shows total assets of $2.33 billion, including current assets of $672.9 million and goodwill of $807.0 million. Total liabilities were $1.29 billion, with long-term debt of $834.2 million. Shareholders' equity was $1.03 billion, resulting in a debt-to-equity ratio of 0.81.
The provided document does not contain management guidance, strategic priorities, or specific risk factors for future periods. No forward-looking statements, projections, or outlook information is included in the available financial data. The filing presents historical financial results for fiscal year 2025 without commentary on future expectations, market conditions, or strategic initiatives. Investors should refer to the complete 10-K filing for any management discussion and analysis sections that may contain forward-looking information not included in this extracted data set.